Clinical trialNCT06816992RecruitingPhase 1Interventional

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

SponsorORIC PharmaceuticalsEnrollment76EGFR Exon 20 Insertion MutationsEGFR-mutated NSCLCNSCLCSolid Tumors

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-114 in combination with subcutaneous (SC) amivantamab in patients with advanced or metastatic NSCLC harboring an EGFR exon 20 insertion mutation.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Pratik S. Multani, MD, MS
ORIC Pharmaceuticals
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
Not, yet, recruiting

Canada

the Princess Margaret Hospital
Toronto, Ontario, Canada
Not, yet, recruiting

United States

Nyu Langone Health
New York, New York, United States
Recruiting
Virginia Cancer Specialists
Fairfax, Virginia, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

ORIC-114 Dose 1 + amivantamabORIC-114 Dose 2 + amivantamabORIC-114 Dose 3 + amivantamab

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 27 Feb 2025
Primary completion: 31 Dec 2026
Completion: 31 Dec 2027
Last update posted: 24 Apr 2026
Registered enrollment: 76
Registry id: NCT06816992

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.